The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies
Cancers · 30.12.2024 · 17 (1) · 82
DOI: 10.3390/cancers17010082 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.12.2024. Verfasst von Anh L Nguyen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Lisa Dean Moseley Foundation, Cawley Center for Translational Cancer Research Fund.
Abstract (Originalsprache)
Fibroblast growth factors (FGFs) have diverse functions in the regulation of cell proliferation and differentiation in development, tissue maintenance, wound repair, and angiogenesis. The goal of this review paper is to (i) deliberate on the role of FGFs and FGF receptors (FGFRs) in different cancers, (ii) present advances in FGF-targeted cancer therapies, and (iii) explore cell signaling mechanisms that explain how FGF expression becomes dysregulated during cancer development. FGF is often mutated and overexpressed in cancer and the different FGF and FGFR isoforms have unique expression patterns and distinct roles in different cancers. Among the FGF members, the FGF 15/19 subfamily is particularly interesting because of its unique protein structure and role in endocrine function. The abnormal expression of FGFs in different cancer types (breast, colorectal, hepatobiliary, bronchogenic, and others) is examined and correlated with patient prognosis. The classification of FGF ligands based on their mode of action, whether autocrine, paracrine, endocrine, or intracrine, is illustrated, and an analysis of the binding specificity of FGFs to FGFRs is also provided. Moreover, the latest advances in cancer therapeutic strategies involving small molecules, ligand traps, and monoclonal antibody-based FGF inhibitors are presented. Lastly, we discuss how the dysregulation of FGF and FGFR expression affects FGF signaling and its role in cancer development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
- Center for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, 4701 Ogletown-Stanton Road, Newark, DE 19713, USA.
- Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA.
ORCID-Profile: Anh L Nguyen
Förderung
- NIGMS NIH HHS
- Lisa Dean Moseley Foundation
- Cawley Center for Translational Cancer Research Fund
- Carpenter Foundation
- University of Delaware Department of Biological Sciences
- INBRE NIH/NIGMS
Zitieren
APA
Nguyen, A. L., Facey, C. O. B., & Boman, B. M. (2024). The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies. Cancers, 17(1), 82. https://doi.org/10.3390/cancers17010082
Vancouver
Nguyen AL, Facey COB, Boman BM. The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies. Cancers. 2024;17(1):82. doi:10.3390/cancers17010082
BibTeX
@article{Nguyen2024,
author = {Nguyen, Anh L and Facey, Caroline O B and Boman, Bruce M},
title = {The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies},
journal = {Cancers},
year = {2024},
volume = {17},
number = {1},
pages = {82},
doi = {10.3390/cancers17010082}
}
EUVIMED